What ApoB is
Apolipoprotein B-100 (ApoB) is the primary structural protein of all atherogenic lipoproteins — the particles that drive atherosclerosis. These include LDL (low-density lipoprotein), VLDL (very-low-density lipoprotein), IDL (intermediate-density lipoprotein), and Lp(a). Each of these particles carries exactly one ApoB molecule.
This 1:1 ratio makes ApoB a direct particle counter. Measuring serum ApoB tells you exactly how many atherogenic lipoprotein particles are circulating in your bloodstream at the moment of testing.
Why one ApoB = one particle
Unlike cholesterol, which can exist in varying amounts per particle, every single atherogenic lipoprotein has exactly one ApoB-100 molecule anchoring its structure. This makes ApoB the most direct and unambiguous count of atherogenic particles available through a standard blood test.
When an LDL particle enters the arterial wall to initiate an atherosclerotic plaque, it brings with it exactly one ApoB molecule. The cardiovascular risk is driven by how many particles enter the artery — not how much cholesterol those particles collectively carry.
Why ApoB is more accurate than LDL-C
LDL-C measures cholesterol mass — but particles can vary in cholesterol content. Patients with metabolic syndrome, insulin resistance, or South Asian genetics disproportionately produce small, dense LDL particles that carry less cholesterol per particle. In this pattern:
- LDL-C may appear normal or even low (less cholesterol per particle)
- ApoB is elevated (many particles, each with small cholesterol payload)
- Actual cardiovascular risk is HIGH — many particles entering the artery
LDL-C would miss this risk entirely. ApoB captures it. This discordance (low LDL-C but high ApoB) is particularly common in South Asians and is a major reason for underestimated cardiovascular risk in India.
The longevity medicine consensus
Most leading longevity cardiologists — including those whose work is most frequently cited in evidence-based longevity medicine — consider ApoB the single most important cardiovascular biomarker. The argument is that LDL-C should be replaced as the primary cardiovascular test by ApoB in standard clinical practice. This shift is gradually occurring in updated cardiology guidelines internationally.
Testing in India
ApoB testing is widely available across India at major diagnostic chains:
- SRL Diagnostics — ApoB test available nationwide
- Metropolis Healthcare — ApoB + ApoA1 ratio panels
- Dr Lal PathLabs — ApoB available in standard and advanced lipid panels
- Thyrocare — included in several comprehensive health panels
Cost: approximately ₹400–800 for ApoB alone; ₹800–1,500 for advanced lipid panel including ApoB, Lp(a), and LDL subfractions.
ApoB target ranges by risk category
| ApoB Level | Risk Category | Who Should Target This | Primary Interventions |
|---|---|---|---|
| <60 mg/dL | Optimal (high risk) | Existing CVD, elevated Lp(a), diabetes, strong family history | Statin + PCSK9 inhibitor; berberine; aggressive diet |
| 60–80 mg/dL | Optimal (low/moderate risk) | Longevity target for most healthy adults | Diet, berberine, exercise; statin if needed |
| 80–100 mg/dL | Borderline elevated | Above longevity target; intervention warranted | Dietary saturated fat reduction; berberine; psyllium husk; retest in 3 months |
| 100–130 mg/dL | Elevated | Significant risk; lab "normal" but not optimal | Berberine, dietary changes; consider statin with risk factors |
| >130 mg/dL | High — requires treatment | Familial hypercholesterolaemia possible; high cardiovascular risk | Physician evaluation; statin therapy typically indicated |
What moves ApoB
Raises ApoB: dietary saturated fat, trans fats, refined carbohydrates and sugar, high-fructose diet, metabolic syndrome, insulin resistance.
Lowers ApoB:
- Statins — 30–50% reduction; most evidence-backed intervention
- PCSK9 inhibitors (evolocumab, alirocumab) — 50–60% reduction; injectable, expensive but highly effective
- Berberine — 15–25% reduction via PCSK9 inhibition; available OTC in India
- Dietary changes — reducing saturated fat and replacing with polyunsaturated fat; 5–15% reduction
- Psyllium husk — 5–7% ApoB reduction via bile acid binding
- Weight loss — meaningful reduction proportional to fat mass lost
Lp(a) contribution
Lp(a) is an LDL-like particle that also contains one ApoB molecule. When you test ApoB, Lp(a) particles are included in the count. If you have elevated Lp(a), your ApoB will be higher than what LDL particles alone would account for. This is another reason to test Lp(a) separately alongside ApoB.
How often to test
Annually if at target and stable. Every 6 months if above target or actively adjusting treatment. After starting or changing a lipid-lowering intervention, retest at 6–8 weeks to confirm response.
Frequently asked questions
What is ApoB and why is it better than LDL cholesterol?
ApoB directly counts atherogenic particles — one ApoB per particle. LDL-C measures cholesterol mass, which can be misleadingly low when particles are small and numerous. ApoB captures risk that LDL-C misses, especially in South Asians with insulin resistance.
How much does the ApoB test cost in India?
₹400–800 for ApoB alone at SRL, Metropolis, Dr Lal PathLabs, or Thyrocare. Advanced lipid panels including ApoB and Lp(a) cost ₹800–1,500. Highly cost-effective given its superiority to standard LDL-C for risk assessment.
What is the optimal ApoB level for longevity?
Below 80 mg/dL for low-to-moderate risk. Below 60 mg/dL for high-risk individuals. Clinical guidelines consider above 100 mg/dL as elevated — longevity medicine targets are more aggressive.
How do I lower ApoB in India?
Statins offer 30–50% reduction. Berberine 500mg twice daily lowers ApoB 15–25% via PCSK9 inhibition. Reducing saturated fat, refined carbohydrates, and losing weight all help. Psyllium husk 5–10g/day provides an additional 5–7% reduction.